Medicus Pharma Ltd. filed a current report on November 13, 2026, disclosing a debt-to-equity exchange with Streeterville Capital, LLC and a registered direct offering that raised approximately $3.0 million in gross proceeds.

Key Highlights

  • Exchange closed: $10.5 million in principal from the A-1 Note was exchanged for 105,000 non-convertible, non-voting preferred shares at $100 per share.
  • A-1 Note reduced: Following the exchange, approximately $4.2 million of principal and accrued and unpaid interest remains outstanding under the A Notes combined.
  • No cash received: The company disclosed it did not receive any cash proceeds from the exchange transaction.
  • Registered direct offering: The company agreed to issue 97,973 common shares at $1.72 per share and pre-funded warrants to purchase up to 1,646,213 common shares at $1.7199 per warrant.
  • Gross proceeds: Aggregate gross proceeds from the offering were approximately $3.0 million, before deducting estimated offering expenses.
  • Preferred share terms: The preferred shares carry cumulative dividends at 8% per annum, payable in kind, and are redeemable at the company's option at $100 per share.

Medicus Pharma Restructures A-1 Note and Closes $3.0 Million Offering on the Same Day

According to the filing, on November 13, 2026, Medicus Pharma Ltd. (NASDAQ:MDCX) entered into and closed an exchange agreement with Streeterville Capital, LLC. Under the Exchange Agreement, $10.5 million in principal from the company's Secured Promissory Note A-1, originally issued on May 27, 2026 in the principal amount of $12,864,225, was partitioned into a new note and then exchanged for 105,000 non-convertible, non-voting preferred shares at an issue price of $100 per share. The filing states the Partitioned Note was cancelled and the corresponding indebtedness was extinguished at closing.

The company disclosed that the unexchanged balance of the A-1 Note remains outstanding under its original terms. The A-2 Note, issued September 1, 2026, was not affected by the exchange. The filing states that approximately $4.2 million of principal and accrued and unpaid interest remains outstanding under the A Notes collectively, and that $8.2 million outstanding under the company's Secured Promissory Note B, also issued May 27, 2026, was similarly unaffected. The company disclosed it expects to classify the preferred shares as permanent shareholders' equity.

Separately, also on November 13, 2026, the company entered into a securities purchase agreement for a registered direct offering, issuing 97,973 common shares at $1.72 per share and pre-funded warrants to purchase up to 1,646,213 common shares at $1.7199 per warrant, representing an aggregate of 1,744,186 common shares including pre-funded warrant shares. The filing states gross proceeds were approximately $3.0 million before estimated offering expenses. The company disclosed it did not engage a placement agent or underwriter and paid no underwriting discounts or commissions. The offering price per share was the closing price of the common shares on the Nasdaq Capital Market on November 12, 2026.

What Was Disclosed

Medicus Pharma reported a debt-to-equity exchange eliminating $10.5 million in note principal, leaving approximately $4.2 million outstanding under the A Notes, alongside a registered direct offering generating approximately $3.0 million in gross proceeds, all effective November 13, 2026.